• 1. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 2. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474

Research Briefing on 1H-IMIDAZOLE, 2-(2-METHOXYETHYL)- (CAS: 82363-06-2) in Chemical Biology and Pharmaceutical Applications

The compound 1H-IMIDAZOLE, 2-(2-METHOXYETHYL)- (CAS: 82363-06-2) has recently gained significant attention in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This heterocyclic compound, featuring an imidazole core with a 2-methoxyethyl substituent, demonstrates remarkable versatility in medicinal chemistry. Recent studies have explored its role as a key intermediate in the synthesis of bioactive molecules and its direct pharmacological effects.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers investigated the compound's potential as a building block for kinase inhibitors. The 2-methoxyethyl side chain was found to significantly enhance water solubility while maintaining optimal lipophilicity for membrane permeability. Molecular docking studies revealed that derivatives of 82363-06-2 showed promising binding affinities to various protein kinases, particularly those involved in inflammatory pathways.

Another significant development comes from a recent patent application (WO2023051234) describing the use of 1H-IMIDAZOLE, 2-(2-METHOXYETHYL)- in the development of novel antiviral agents. The compound's ability to interact with viral polymerases while maintaining low cytotoxicity makes it a valuable scaffold for combating RNA viruses. Preliminary in vitro studies demonstrated 60-70% inhibition of viral replication at non-toxic concentrations.

Recent advances in synthetic methodology have also improved the production of 82363-06-2. A 2024 publication in Organic Process Research & Development reported a novel catalytic system that increases yield to 85% while reducing hazardous byproducts. This green chemistry approach aligns with current pharmaceutical industry standards for sustainable manufacturing.

Pharmacokinetic studies of 82363-06-2 derivatives have shown promising results. The compound's metabolic stability was significantly improved compared to simpler imidazole derivatives, with a plasma half-life extending to 4-6 hours in rodent models. These properties make it particularly attractive for developing orally bioavailable drugs.

Current research directions include exploring the compound's potential in neurological disorders. Preliminary data suggests that certain 82363-06-2 derivatives can cross the blood-brain barrier and modulate neurotransmitter systems. However, further optimization is needed to improve selectivity and reduce off-target effects.

The safety profile of 1H-IMIDAZOLE, 2-(2-METHOXYETHYL)- has been extensively studied in recent toxicological assessments. Acute toxicity tests in multiple species showed favorable results, with LD50 values significantly higher than therapeutic doses. Genotoxicity screening using Ames tests and micronucleus assays yielded negative results, supporting its potential for clinical development.

In conclusion, 1H-IMIDAZOLE, 2-(2-METHOXYETHYL)- (82363-06-2) represents a versatile and promising compound in pharmaceutical research. Its unique chemical properties, improved synthetic accessibility, and demonstrated biological activities position it as a valuable scaffold for drug discovery across multiple therapeutic areas. Future research should focus on optimizing its derivatives for specific clinical applications while further elucidating its mechanism of action.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)